ACE and cardiovascular disorder: The landmark EMPA-REG trial for patients with T2DM demonstrated that EMPA decreased cardiovascular mortality in patients with cardiovascular disease already receiving the standard of care (i.e., ACE inhibitors or ARBs) [18].